Published in Mol Cell on September 24, 2009
Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell (2010) 7.20
Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest (2010) 2.37
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation (2010) 2.32
MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle (2010) 2.18
Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci U S A (2010) 2.11
miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ (2010) 2.09
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A (2012) 2.07
MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One (2010) 2.05
Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol (2010) 2.03
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol (2010) 2.03
An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem (2009) 1.90
MiR-210--micromanager of the hypoxia pathway. Trends Mol Med (2010) 1.90
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica (2010) 1.83
miR-27b controls venous specification and tip cell fate. Blood (2011) 1.79
MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem (2010) 1.76
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer (2011) 1.74
Signaling pathways in renal cell carcinoma. Cancer Biol Ther (2010) 1.58
miR-210: the master hypoxamir. Microcirculation (2012) 1.56
Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity. Radiat Res (2015) 1.53
microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol (2011) 1.45
Identification and expression profiling of microRNAs in the brain, liver and gonads of marine medaka (Oryzias melastigma) and in response to hypoxia. PLoS One (2014) 1.42
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J (2010) 1.41
Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One (2012) 1.41
MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis (2013) 1.37
The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer (2011) 1.35
Redox regulation of mitochondrial function. Antioxid Redox Signal (2012) 1.34
Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med (2013) 1.30
Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J Clin Invest (2013) 1.30
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest (2012) 1.29
Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol (2014) 1.27
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. Placenta (2012) 1.26
Trash or Treasure: extracellular microRNAs and cell-to-cell communication. Front Genet (2013) 1.25
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One (2013) 1.23
Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci (2012) 1.23
A CHOP-regulated microRNA controls rhodopsin expression. J Cell Biol (2011) 1.22
Transcriptional regulation of mammalian miRNA genes. Genomics (2010) 1.16
MicroRNAs in cardiac disease. Transl Res (2011) 1.13
Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogenesis (2011) 1.13
Invited review: decoding the microRNA response to hypoxia. Pflugers Arch (2011) 1.12
Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res (2014) 1.12
MicroRNAs-role in lung cancer. Dis Markers (2014) 1.11
MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res (2012) 1.11
miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol (2012) 1.09
MicroRNA regulons in tumor microenvironment. Oncogene (2014) 1.08
The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med (2010) 1.08
Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One (2012) 1.08
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle (2010) 1.07
Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget (2014) 1.07
miR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies. Am J Pathol (2011) 1.06
Post-Transcriptional Control of the Hypoxic Response by RNA-Binding Proteins and MicroRNAs. Front Mol Neurosci (2011) 1.06
Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. PLoS One (2011) 1.05
Analysis of circulating microRNAs in adrenocortical tumors. Lab Invest (2013) 1.04
Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin (2013) 1.04
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov (2016) 1.03
Gene expression and hypoxia in breast cancer. Genome Med (2011) 1.02
Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci (2013) 1.02
Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One (2014) 1.01
mir-210: a sensor for hypoxic stress during tumorigenesis. Mol Cell (2009) 1.01
Holding our breath: The emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm Circ (2012) 1.01
EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene (2014) 1.00
Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PLoS One (2012) 1.00
Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One (2014) 1.00
MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci (2013) 0.99
Micromanaging Iron Homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem (2012) 0.98
MicroRNA profiles classify papillary renal cell carcinoma subtypes. Br J Cancer (2013) 0.97
MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs. PLoS One (2015) 0.97
Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol (2014) 0.96
miR-210: fine-tuning the hypoxic response. Adv Exp Med Biol (2014) 0.95
Hypoxia-inducible factor 1-α induces miR-210 in normoxic differentiating myoblasts. J Biol Chem (2012) 0.95
Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer. Mol Cancer (2014) 0.94
Impaired mitochondrial function in human placenta with increased maternal adiposity. Am J Physiol Endocrinol Metab (2014) 0.94
Human placental microRNAs and preeclampsia. Biol Reprod (2013) 0.94
Regulation of angiogenesis by hypoxia: the role of microRNA. Cell Mol Biol Lett (2012) 0.94
Vav family exchange factors: an integrated regulatory and functional view. Small GTPases (2014) 0.93
EAF2 suppresses hypoxia-induced factor 1α transcriptional activity by disrupting its interaction with coactivator CBP/p300. Mol Cell Biol (2014) 0.92
HypoxamiRs and cancer: from biology to targeted therapy. Antioxid Redox Signal (2013) 0.92
HIF-1 regulates iron homeostasis in Caenorhabditis elegans by activation and inhibition of genes involved in iron uptake and storage. PLoS Genet (2011) 0.92
Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes. Dev Neurosci (2011) 0.92
MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic Acids Res (2014) 0.92
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell (2016) 0.92
miR-210 promotes IPF fibroblast proliferation in response to hypoxia. Am J Physiol Lung Cell Mol Physiol (2014) 0.91
Hypoxia-inducible miR-182 enhances HIF1α signaling via targeting PHD2 and FIH1 in prostate cancer. Sci Rep (2015) 0.91
The Role of miRNAs as Key Regulators in the Neoplastic Microenvironment. Mol Biol Int (2011) 0.90
Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg (2011) 0.90
MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma. Oncogene (2014) 0.90
Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene (2014) 0.89
The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma. Arch Biochem Biophys (2014) 0.89
TLR3-induced placental miR-210 down-regulates the STAT6/interleukin-4 pathway. PLoS One (2013) 0.89
MicroRNAs in Vascular Biology. Int J Vasc Med (2012) 0.89
A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget (2015) 0.88
Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis. Dis Markers (2014) 0.88
Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma. J Oncol (2015) 0.88
MicroRNAs and esophageal cancer. J Gastrointest Oncol (2010) 0.88
MicroRNAs in Head and Neck Cancer. Int J Dent (2013) 0.88
Epigenetics and microRNAs in preeclampsia. Clin Exp Hypertens (2012) 0.88
MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone. PLoS One (2011) 0.88
Trophoblasts, invasion, and microRNA. Front Genet (2013) 0.88
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Molecular portraits of human breast tumours. Nature (2000) 94.14
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
Human MicroRNA targets. PLoS Biol (2004) 34.51
The impact of microRNAs on protein output. Nature (2008) 32.39
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 22.06
The role of site accessibility in microRNA target recognition. Nat Genet (2007) 18.52
Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol (2008) 12.35
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
microRNA target predictions in animals. Nat Genet (2006) 10.76
A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A (2006) 10.09
Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 7.24
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 6.91
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Isolation of microRNA targets by miRNP immunopurification. RNA (2007) 5.50
A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci U S A (2007) 5.16
Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biol (2007) 4.96
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet (2007) 4.73
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem (2008) 4.69
How do microRNAs regulate gene expression? Sci STKE (2007) 4.64
Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev (1998) 4.29
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem (2006) 3.43
Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol (2003) 3.10
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle (2009) 3.07
Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem (2000) 2.70
BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med (2003) 2.62
Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev (2007) 2.52
Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev (2007) 2.07
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res (2007) 2.06
Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol (2005) 1.95
Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett (2008) 1.75
p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol (2001) 1.53
Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells (2006) 1.47
Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem (2002) 1.32
Functional analysis of p53 binding under differential stresses. Mol Cell Biol (2006) 1.25
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol (2002) 5.39
Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys (2008) 5.03
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol (2008) 4.39
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol (2005) 4.00
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol (2009) 3.99
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell (2002) 3.86
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res (2007) 3.45
JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell (2004) 3.30
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res (2004) 3.24
Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys (2004) 3.21
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med (2011) 2.97
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell (2008) 2.38
HIF1alpha delays premature senescence through the activation of MIF. Genes Dev (2006) 2.37
The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell (2005) 2.34
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res (2004) 2.33
Sample classification from protein mass spectrometry, by 'peak probability contrasts'. Bioinformatics (2004) 2.28
Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol (2006) 2.27
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2009) 2.26
The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell (2012) 2.25
Investigating hypoxic tumor physiology through gene expression patterns. Oncogene (2003) 2.24
Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol (2010) 2.17
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.14
Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res (2006) 2.13
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2005) 2.10
ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem (2003) 2.09
Oropharyngeal carcinoma related to human papillomavirus. BMJ (2010) 2.09
Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev (2007) 2.07
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol (2010) 2.03
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol (2007) 2.03
Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol (2002) 2.03
Hypoxic gene expression and metastasis. Cancer Metastasis Rev (2004) 2.01
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Statistical methods of background correction for Illumina BeadArray data. Bioinformatics (2009) 1.99
Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol Cell Biol (2003) 1.99
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res (2003) 1.96
Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol (2005) 1.95
Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. J Cell Biol (2007) 1.95
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev (2010) 1.92
OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell (2005) 1.91
MiR-210--micromanager of the hypoxia pathway. Trends Mol Med (2010) 1.90
Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest (2008) 1.89
Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem (2002) 1.88
Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys (2009) 1.88
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell (2008) 1.88
Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.85
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
ATM activation and signaling under hypoxic conditions. Mol Cell Biol (2008) 1.84
The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys (2003) 1.83
Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell (2009) 1.82
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2012) 1.77
Effect of reduced oxygen tension on chondrogenesis and osteogenesis in adipose-derived mesenchymal cells. Am J Physiol Cell Physiol (2005) 1.76
Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys (2009) 1.75
Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.75
Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia. Circulation (2007) 1.71
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res (2006) 1.71
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res (2011) 1.71
Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.69
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Results of a phase 2 study examining the effects of omitting elective neck irradiation to nodal levels IV and Vb in patients with N(0-1) nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 1.68
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res (2009) 1.64
Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Lett (2006) 1.63
Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck (2007) 1.63
MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol (2011) 1.61
Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.60
Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts. J Biol Chem (2004) 1.60
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development (2004) 1.58
Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther (2003) 1.56
Comparison of treatment results between adult and juvenile nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2009) 1.54
Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res (2006) 1.53
Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res (2005) 1.52
IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys (2008) 1.51
Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.51